Johnson & Johnson and UnitedHealth Report the Same Morning. Here’s What Matters.
Two healthcare giants drop their third-quarter numbers on the same morning, and what each reveals about drug costs, insurance margins, and guidance ranges will set the tone for the entire sector heading into 2027.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and UnitedHealth Group (NYSE:UNH) both report third-quarter results before the opening bell on Tuesday, October 13, 2026. One is a drug-and-device maker and the other a managed-care giant, so the morning will test the entire healthcare sector at once.
Johnson & Johnson posts its release at approximately 6:45 a.m. ET and holds its call at 8:30 a.m. ET. UnitedHealth Group’s call starts at 8:00 a.m. ET.
Johnson & Johnson’s Defensive Label Meets a Strong Chart
On October 2, Jim Cramer noted that investors are avoiding defensive names: “They don’t want to buy the safety of a J&J, which I still think is what you should be buying here.” The price data shows shares up 26.1% year to date and 36.0% over the past year. The only dip is a 1.8% slide over the past month.
Last quarter, adjusted EPS of $2.90 beat estimates on revenue of $25.31 billion. Innovative Medicine grew 7.8% and MedTech rose 4.5%. Management also raised full-year adjusted EPS guidance to $11.60 to $11.75.
Stelara fell 55.2% on biosimilar competition, while Tremfya rose 72.5%. Expect questions on Firefly Bio, which guidance leaves out, as well as Ottava’s FDA path and Abiomed’s 2% decline. The full-year EPS consensus of $11.0734 falls below the guided range of $11.60 to $11.75.
Consensus Points in Opposite Directions
| Estimate (YoY Change) | Johnson & Johnson | UnitedHealth |
|---|---|---|
| Q3 EPS | $2.5133 (−10.24%) | $4.1495 (+42.11%) |
| Q3 Revenue | $25.38B (+5.76%) | $111.49B (−1.48%) |
| FY2026 EPS | $11.0734 (+2.63%) | $19.8674 (+21.51%) |
| FY2026 Revenue | $101.42B (+7.67%) | $447.09B (−0.11%) |
UnitedHealth’s Medicare Relief Versus Commercial Strain
UnitedHealth shares are up 12.8% year to date but down 1.1% over the past month. Analysts have revised their estimates higher anyway. Third-quarter EPS consensus rose to $4.1495 from $3.7557, 90 days ago.
Second-quarter EPS reached $6.38 as the medical care ratio improved to 86.7% from 89.4%. That figure included $860 million of positive reserve development. Full-year guidance calls for adjusted EPS of $19.50 to $20.00 and a medical care ratio of 88.1%.
Medicare cost trend ran below plan. Commercial trend is running “modestly above 11%,” and management says this pushes full commercial margin recovery past 2027. Medicare Advantage membership has shrunk by 965,000 since year-end. Optum Health revenue fell 5% on about 700,000 fewer value-based care patients.
Where the Read-Across Holds and Where It Breaks
Drug spending links the two companies. UnitedHealth named specialty and anti-inflammatory drugs among its commercial cost drivers, and that category includes J&J’s immunology franchise. Tremfya growth counts as revenue for J&J and as cost pressure for payers.
Beyond that, the link is thin. J&J’s results depend on launches and patent cliffs. UnitedHealth’s depend on use, pricing, and reserves.
What Would Count as a Real Surprise
For J&J, look for any change to the $11.60 to $11.75 range, or Stelara erosion worse than 55.2%. For UnitedHealth, check whether the 88.1% medical care ratio target holds and whether commercial trend moves further above 11%. Those four markers will indicate which story is driving the healthcare sector into 2027.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, moderating workshop sessions at regional conventions.
